RE:June 28 corporate presentationThis chart is the same as the one from the
MD&A which includes the 38 phase 2 patients treated and the 3 phase 1 patients. It represents evaluable patients, so the pending patients are excluded.
Of evaluable patients at 450 days there is a
CR of 23% and a
total response of 32% (CR+PR)
Excluding the pending patients results in an over-representation of the first 12 undertreated patients. If we want to see the
maximum possible CR rates and total response rates at 450 days for the first 38+3=41 patients we can add the 19 pending patients back in.
The maximum possible
450 day CR rate is 58.5% The maximum possible
450 day total response rate is 63.4% IMHO we will get closer and closer to these numbers as the trial progresses.
These rates are in line with the CR rates of the first 3 full-dose patients from our phase 1, the 3 year rates of photofrin pdt (60%)
https://www.sciencedirect.com/science/article/abs/pii/S0090429599800806 and also the 30 month CR rates of systemically delivered radachlorin pdt using red light for NMIBC - also 60% - https://pubmed.ncbi.nlm.nih.gov/23648222/
ScienceFirst wrote: Page 10 of the June 28 Corporate presentation shows the efficacy %.
The last line of that table shows what is important to the FDA; CR + PR
Presentation-2022.pdf (theralase.com)